Abbott Announces FDA Approval and U.S. Launch of Next-Generation XIENCE Xpeditionâ„¢ Drug Eluting Stent System

[at noodls] – Abbott Park, Illinois (NYSE: ABT) – Abbott today announced that the XIENCE Xpeditionâ„¢ Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching … more

View todays social media effects on ABT

View the latest stocks trending across Twitter. Click to view dashboard

See who Abbott is hiring next, click here to view